These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 3303316)

  • 1. [Interleukin-2: molecular, physiological and pathophysiological bases and possible significance for clinical practice].
    Borradori L; Knellwolf M; Morell A
    Schweiz Med Wochenschr; 1987 Jun; 117(25):945-51. PubMed ID: 3303316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.
    Robertson MJ; Cameron C; Lazo S; Cochran KJ; Voss SD; Ritz J
    Nat Immun; 1996-1997; 15(5):213-26. PubMed ID: 9390270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic.
    Vujanovic NL; Rabinowich H; Lee YJ; Jost L; Herberman RB; Whiteside TL
    Cell Immunol; 1993 Oct; 151(1):133-57. PubMed ID: 8402925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients.
    Zerhouni B; Sanhadji K; Kehrli L; Livrozet JM; Touraine JL
    Thymus; 1997; 24(3):147-56. PubMed ID: 9151380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
    Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
    Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
    Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells.
    London L; Perussia B; Trinchieri G
    J Immunol; 1986 Dec; 137(12):3845-54. PubMed ID: 3491151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
    Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
    Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin modulation of natural killer activity in human peripheral lymphocytes.
    Naldini A; Carney DH
    Cell Immunol; 1996 Aug; 172(1):35-42. PubMed ID: 8806804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
    Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
    Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
    Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
    Tam YK; Martinson JA; Doligosa K; Klingemann HG
    Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Studies on adoptive immunotherapy using recombinant interleukin 2].
    Sugiyama Y; Takao H; Saji S; Sakata K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1307-13. PubMed ID: 3488028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturin: a potent bio-immunomodifier in experimental studies and clinical trials.
    Shen RN; Lu L; Jia XQ; Wong ML; Kaiser HE
    In Vivo; 1996; 10(2):201-9. PubMed ID: 8744801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.